MarginsXMarginsX
Home › Markets › TLPPF

Telix Pharmaceuticals Ltd (TLPPF)

TLPPF is quoted over the counter, not listed on an exchange. Telix Pharmaceuticals Ltd files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Last trade · November 11, 2026
$9.43
No trades since Nov 11, 2026; later closes repeat the last quote
1-year return
-2.9%
Market cap
The company also trades on Nasdaq as TLX; this OTC line is another class or a foreign line, so its cap is not computed
P/E and P/S
Needs a market cap · Needs a market cap
On fiscal year to December 31, 2025 (20-F)

Closes: Yahoo Finance daily closes, last bar 2026-11-13.

Profile

FieldValue
TickerTLPPF, quoted over the counter
SEC CIK0002007191
OTC Markets tierPink (price source, 2026-11-13)
SEC industry codePharmaceutical Preparations
Business addressNorth Melbourne, Australia
Incorporated inAustralia

Warning signs

Cash runway
98.4 months
$141.9M cash at December 31, 2025
Share count, 1 year
+1.2%
2024-12-31 to 2025-12-31
Going-concern doubt
No
20-F filed February 20, 2026
Insider net buying, 12 months
$1.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-02-20
Cash and burn$141.9M cash; operating cash flow -$4.3M a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-02-20
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers, Melbourne, AustraliaPCAOB Form AP 2026-03-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1.0M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$803.8M-$7.1M-$17.3M$141.9M$405.0M$803.8M20-F 2026-02-20
FY 2024
2024-12-31
$516.6M$33.7M$27.5M$440.0M$353.6M$516.6M20-F 2026-02-20
FY 2023
2023-12-31
$333.0M$4.2M$14.3M$84.3M$6.6M$333.0M20-F 2026-02-20

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentDRS2024-09-13
Latest annual report20-F2026-02-20
Latest quarterly / interim6-K2026-10-29

Source: SEC EDGAR submissions feed, 109 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier